Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia.
Oztas
Pinar
P
Erbasi
Servet
S
Lenk
Nurdan
N
Polat
Muhterem
M
Han
Ozge
O
Artuz
Ferda
F
Alli
Nuran
N
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001549:Benzamides; D003873:Dermatitis, Exfoliative / Q000139:chemically induced*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate